Author(s): Van Doren BA, FoulksRodriguez KA, Yarborough W
Abstract Share this page
Abstract BACKGROUND: Opioid dependency currently affects over 2.5 million patients in the United States and is increasing in incidence. Office-based opioid therapy with buprenorphine-naloxone provides greater patient access to treatment and has significantly improved therapeutic outcomes. METHODS: We conducted a study of 100 consecutive patients treated for opioid dependence with buprenorphine-naloxone in a single provider's community-based internal medicine practice. The primary outcome measures were retention in therapy, wellness, and abstinence from ongoing drug use. Data were obtained from frequent physical examinations, self-report data, and periodic urine drug screening. RESULTS: The retention rate in therapy was 75\%. A multidimensional evaluation of wellness improved in 75\% of the patients. Eighty-five percent reported no opiate relapse during therapy. CONCLUSION: Office-based opioid therapy with buprenorphine-naloxone has provided greater access to therapy with improved therapeutic outcomes. Our findings support the mounting literature that more patients should be offered office-based opioid therapy for opioid dependency.
This article was published in J Okla State Med Assoc
and referenced in Journal of Bioequivalence & Bioavailability